Veritas Pharma
Lui Franciosi is the CEO of Veritas Pharma (CSE:VRT), a discovery & development company focused on scientifically finding new medicinal cannabis cultivars for specific disease conditions. In particular, his company’s goals are to chemically profile different marijuana cultivars; to pharmacologically profile those same cultivars in the search for disease specific strains; and to perform clinical trials to establish the clinical utility of a patented cultivar. Dr. Franciosi has more than 20 years experience conducting pharmaceutical and medical device studies in academia and industry. Previously, he was the Chief Operating Officer of Verona Pharma plc, a London UK company on the London Stock Exchange AIM. Prior to this work, he completed his post-doctoral research in COPD progression modelling at the Clinical Pharmacology & Discovery Medicine Unit, GlaxoSmithKline, UK and the Leiden/Amsterdam Centre for Drug Research, The Netherlands. He was also a clinical trial manager & monitor with the public company Nortran Pharmaceuticals (now Cardiome Pharma) to investigate novel antiarrhythmics and peripheral analgesics. He has investigated a novel wound management system at Aero-therapeutic Wound Management, Canada. Based on these experiences, he obtained his Doctorate & Masters degrees at The University of British Columbia (UBC), Canada as well as pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, department of Anesthesiology, Pharmacology & Therapeutics.